Altamira Therapeutics Ltd (CYTO)

[Anite]

to receive milestone payments of up to $55 million as well as royalties. The milestones relate to certain development or regulatory milestones, including:

the opening of an IND, a successful Phase 3 and regulatory approval for AM-125 in vertigo ($25 million)

the regulatory approval of AM-101 in acute inner ear tinnitus ($10 million)

the regulatory approval of AM-111 in acute inner ear hearing loss ($10 million)

the grant of a license for Altamira’s RNA delivery technology to Zilentin for certain targets in inner ear disorders ($10 million upfront plus a mid-single digit percentage in royalties on future revenues generated from the sale of drug products making use of the technology)